Germany Link : PharmaMar gibt bei der ASCO 2015 neue Fortschritte in der Onkologie dank seiner Verbindungen YONDELIS® und PM1183 ...
Francia Link : PharmaMar annonce de nouvelles avancées dans le domaine de l'oncologie à l'occasion du congrès de l'ASCO 2015 pour ses composés YONDELIS® et PM1183 ...
Galicia Link : A compañía PharmaMar anuncia novos avances cos compostos ‘Yondelis’ e ‘PM1183′ ...
Italia Link : PharmaMar annuncia nuovi passi avanti in oncologia al meeting ASCO 2015 riguradanti i suoi composti YONDELIS® e PM1183 ...
US Link : Three Trabectedin ( Yondelis ) abstracts have been accepted for presentation and were sponsored by Janssen and PharmaMar ...
PharmaMar Announces New Advances in Oncology at ASCO 2015 for its Compounds YONDELIS® and PM1183 ...
***************************************************************************
PharmaMar Announces new Advances in Oncology at ASCO 2015 for its Compounds YONDELIS® and PM1183 in Small Cell Lung Cancer, Soft Tissue Sarcoma, and Mesothelioma .
*.- Compelling clinical activity of PM1183 in second line, achieving 67% response rate and a progression-free survival of 4.7 months in patients with small cell lung cancer (SCLC), a type of tumor with very limited treatment alternatives
*.- Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS® in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation
*.- Phase 2 data showcase activity of YONDELIS® in malignant pleural mesothelioma, a rare form of lung cancer that is largely related to asbestos exposure and for which effective therapies are lacking
Madrid, May 14, 2015:PharmaMar announces that it will present several clinical studies to showcase the data obtained in various tumor types, including SCLC, soft tissue sarcoma and mesothelioma during the 51st American Society of Clinical Oncology meeting in Chicago (ASCO; May 29-June 2).
Abstracts have been selected for oral presentation, poster discussion session and general poster presentation. The studies presented by the Company will include the first-in-class drug YONDELIS® (trabectedin), and the second-generation of this class, PM1183 (lurbinectedin).
PM1183 is an inhibitor of the transcriptional machinery and a DNA repair complex, which have proven to be crucial in different tumor types, including SCLC, soft tissue sarcoma and ovarian cancer. In addition, these drugs have been shown to have an effect on the tumor microenvironment by targeting tumor-associated macrophages, which is relevant for cancers such as mesothelioma and ovarian cancer, in which chronic inflammation seems to be a hallmark of the disease.
“PharmaMar continues to advance cancer care through the development of innovative anticancer drugs that target tumors in a way that no one is doing. We are identifying new ways to tackle the root of the disease, and our new class of drugs shows efficacy even in difficult-to-treat tumors, such as small cell lung cancer, mesothelioma and soft tissue sarcoma”, says Nadia Badri, MD, VP Medical Affairs, PharmaMar. “The events that will take place this year are crucial for PharmaMar as we move forward in the oncology arena, and this forum is the perfect scenario to feature our clinical programs” .
...
